Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends & Forecast Analysis by Offering (Sample Preparation, Sequencing, Data Analysis/Bioinformatics, Commercial Sequencing/Outsourced Services), Application, End User, and Geography — Forecast to 2036

Thailand Next Generation Sequencing (NGS) Market Size & Forecast

The Thailand next generation sequencing market is projected to reach USD 305.21 million by 2036 from an estimated USD 92.03 million in 2026, at a CAGR of 12.7% during the forecast period from 2026 to 2036. Commercial sequencing and outsourced services account for the largest share of market value through most of the forecast period, reflecting the country's reliance on purchasing sequencing as a completed service rather than building in house capability, while the same segment also registers the fastest growth as more of that outsourced volume migrates into reimbursed clinical pathways.

Key Highlights

• The Thailand NGS market is projected to reach USD 305.21 million by 2036, growing at a CAGR of 12.7% during 2026 to 2036, driven by continued government funding of Genomics Thailand, widening reimbursement coverage, and the growth of outsourced sequencing arrangements.
• The market was valued at USD 80.03 million in 2025 and USD 70.20 million in 2024, and is estimated at USD 92.03 million in 2026.
• Genomics Thailand, launched in 2019 as a five year initiative under the Thailand 4.0 strategic agenda, set out to sequence 50,000 Thai genomes across five disease areas through a consortium of more than 40 national agencies, institutes, medical schools, and hospitals, with the first phase reaching completion during 2025 and a stated intention to expand toward 100,000 samples.
• More than 180,000 new cancer cases were diagnosed in Thailand in 2022 according to GLOBOCAN, and IARC Cancer Tomorrow projections indicate roughly 50% growth in annual incidence by 2045, underscoring the addressable population behind oncology sequencing demand.
• Approximately 30 to 40% of Thai individuals, an estimated 18 to 24 million people, carry thalassemia or another haemoglobin disorder, more than 12,000 infants are born with thalassemia each year, and more than 600,000 patients are covered by the health system and require regular treatment, according to the Ministry of Public Health, sustaining a large reproductive health testing base.
• Reimbursement coverage under the Universal Coverage Scheme has widened in stages, from pharmacogenetic screening for HLA B15:02 and HLA B58:01 covered since 2018, to expanded reimbursable newborn screening for 24 rare diseases in 2023 across seven UHOSNET teaching hospitals, to the more recent addition of BRCA1 and BRCA2 testing for high risk breast cancer patients and their family members.
• Illumina completed its acquisition of SomaLogic on January 30, 2026 for USD 350 million in cash plus up to USD 75 million in milestone payments, extending its position from genomics into proteomics, while Pacific Biosciences divested short read sequencing assets to Illumina during the first quarter of 2026 for a net cash injection of USD 48.1 million.
• By offering, commercial sequencing and outsourced services hold the largest share and the fastest CAGR in 2026, while by application, research and other applications hold the larger share in 2026 but clinical applications is projected to grow faster and overtake research in value before the end of the forecast period.
• By end user, hospitals and diagnostic laboratories are expected to hold the largest share and register the fastest CAGR in 2026, even though academic and research institutes hold the largest sequencing capacity actually installed in the country.

Thailand Next Generation Sequencing (NGS) Market Overview

Click here to: Get Free Sample Pages

The Thailand next generation sequencing market comprises revenue generated from the sale of instruments, consumables, software, and services used to perform massively parallel sequencing of nucleic acids within the country, spanning sample preparation, sequencing, data analysis and bioinformatics, and commercial sequencing and outsourced services, applied across research and clinical settings. Next generation sequencing, also termed massively parallel sequencing, determines the order of nucleotides across many DNA or RNA fragments simultaneously, producing in a single run a volume of sequence data that earlier sequencing methods generated over months.

Thailand occupies an unusual position among middle income countries in genomic medicine. It committed to a national population sequencing program earlier and at a greater scale than most regional peers, launching Genomics Thailand in 2019 with the goal of sequencing 50,000 genomes across cancer, rare and undiagnosed disease, non communicable disease, infectious disease, and pharmacogenomics, and it did so within a universal health coverage framework that reaches approximately 99% of the population, more than 70 million people, of whom around 75% are covered under the Universal Coverage Scheme alone. Care is delivered through a public hospital network of 905 facilities under the Office of the Permanent Secretary, comprising 35 regional, 96 general, and 774 community hospitals, alongside approximately 370 registered private hospitals, several of which serve substantial international patient volumes; Bumrungrad International alone treats more than 520,000 patients annually, including over 58,000 international patients from more than 190 countries, and Thailand counted 65 JCI accredited hospitals and facilities as of November 2025, placing it fourth globally and first in Southeast Asia.

Three conditions define the resulting market. Reimbursement rather than clinical merit is the binding constraint on clinical adoption, since a diagnostic test outside the benefit package must be funded within a fixed case based payment. Interpretive capacity rather than sequencing capacity determines the volume of clinically actionable sequencing the country can perform, a constraint made more acute by the fact that of roughly 1,450 clinical laboratories nationally, around two thirds sit within the government sector under the Ministry of Public Health. And a substantial proportion of demand is met through outsourced arrangements, which weights the market toward services and consumables and away from capital equipment.

The disease burden underlying this demand is characteristic of a country in rapid epidemiological transition. Thailand moved from 7% to 14% of its population aged 65 and above in just 22 years, compared with 114 years in France and 82 years in Sweden, and the International Labour Organization projects that the working age population will decline by approximately 11% by 2040 even as the number of Thais above 65 approaches 17 million. Liver cancer, at roughly 27,400 cases annually, and lung cancer, at roughly 23,700 cases, rank among the most common malignancies by incidence, and breast cancer, the leading cancer among Thai women, recorded incidence growth of 3 to 5% a year between 2008 and 2017. Demand is driven by the continued expansion of Genomics Thailand, increasing clinical adoption in oncology and rare diseases, the growth of outsourced sequencing services, and widening infectious disease and population genomics applications, while limited reimbursement and affordability, high infrastructure and operating costs, and uneven access to advanced genomics infrastructure restrain the growth of this market.

Thailand Next Generation Sequencing (NGS) Market Growth Drivers

The expansion of Genomics Thailand is the single most important driver of sequencing demand in the country. The program commits government funding to sequencing at a scale that commercial demand in Thailand would not independently support, and its cancer workstream alone set out to collect samples from 10,000 cancer patients for whole genome sequencing, while the rare and undiagnosed disease workstream produced the first aggregated Thai variant database from more than 1,000 whole exome sequences. Sequencing capacity has been installed at multiple sites, including DNBSEQ T7RS platforms sited at Burapha University within the Eastern Economic Corridor, and high performance computing operated by the National Science and Technology Development Agency provides the primary data storage and analysis environment for the program.

Increasing Clinical Adoption in Oncology and Rare Diseases

Increasing clinical adoption in oncology and rare diseases is a major driver of demand, supported by an expanding addressable population. More than 180,000 new cancer cases were diagnosed in Thailand in 2022, projected to grow roughly 50% by 2045, and approximately 40% of these cancers are diagnosed at a late stage. Access to treatment has widened alongside testing, with more than 200,000 patients treated at 176 of 192 participating centres under the Cancer Anywhere programme during 2022 alone, an increase of over 70,000 patients against the preceding year. Clinical sequencing in Thai oncology has developed incrementally since single gene testing for KRAS and EGFR mutations became available at large Bangkok university hospitals from 2008, progressing toward panel based profiling as the range of actionable alterations has widened.

Growth of Outsourced Sequencing Services

The growth of outsourced sequencing services shapes the composition of this market as much as its scale. A high throughput sequencing platform requires substantial capital outlay together with a service contract, a continuing supply of consumables, an accredited laboratory environment, and trained personnel, and the unit cost of sequencing on an underutilized platform is materially higher than the price of an outsourced service. This dynamic is reflected directly in segment value, with commercial sequencing and outsourced services projected to grow from USD 38.30 million in 2026 to USD 151.92 million by 2036, and within it, targeted sequencing services alone are estimated at USD 11.52 million in 2026, rising to USD 46.18 million by 2036 at a CAGR of 14.9%.

Thailand Next Generation Sequencing (NGS) Market Growth Opportunities

Expanding Reimbursement Coverage for Genomic Testing

The addition of BRCA1 and BRCA2 testing to the Universal Coverage Scheme benefit package for high risk breast cancer patients and their family members is the most consequential recent reimbursement development in this market. Pharmacogenomic implementation already offers a template for scale, with approximately 3,000 patients at Ramathibodi Hospital alone having benefited from pharmacogenomic and personalized medicine services and received partial medicine reimbursement, illustrating how a single covered test can generate meaningful clinical volume and opening a path for further genomic tests to enter the benefit package over the forecast period.

Integration of Sequencing with Multiomics and Advanced Bioinformatics

Combining genomic sequence with transcriptomic, proteomic, and epigenomic measurement provides a more complete description of biological condition than sequence alone. The Thailand multiomics market, estimated at USD 22.94 million in 2026, is projected to reach USD 94.82 million by 2036 at a CAGR of 15.2%, outpacing the clinical genomics segment even while remaining concentrated in research settings at the principal medical faculties and national research institutes at present.

Key Trends

Shift from Research to Clinical Genomics

Sequencing demand in Thailand originated in academic research and in nationally funded programs, and it is progressively migrating toward clinical service delivery in which sequencing is performed for the management of an individual patient. Research sequencing rewards throughput, flexibility, and cost per base, while clinical sequencing rewards turnaround time, assay validation, regulatory status, reporting quality, and accreditation support, and the funding source correspondingly shifts from research grant to health system budget.

Rising Whole Exome and Whole Genome Sequencing Adoption

The progression toward broader assays reflects falling sequencing cost and improving interpretive capability, along with the recognition that a broader assay reduces the need for sequential testing. Long read suppliers have improved raw accuracy through duplex approaches, and Oxford Nanopore has introduced a short fragment mode supporting fragments of 200 to 500 base pairs that extends nanopore sequencing to the degraded formalin fixed material common in Thai oncology specimens, while Illumina's five base chemistry reads standard bases and methylation states within a single run. In rare disease diagnosis the case for broader assays is strongest, since a targeted panel may miss a causative gene entirely, and the national cancer workstream targeting 10,000 patients is likewise built upon whole genome sequencing.

Thailand Next Generation Sequencing (NGS) Market Analysis: Top Segments

By Offering: Commercial Sequencing/Outsourced Services Dominate the Market in 2026, While the Same Segment Also Grows Fastest

Based on offering, the market is segmented into sample preparation, sequencing, data analysis/bioinformatics, and commercial sequencing/outsourced services. In 2026, commercial sequencing and outsourced services account for the largest share of the market, supported by the outsourcing structure under which institutions purchase sequencing as a completed service rather than establishing capability they cannot keep occupied. The same segment is also projected to register the fastest growth through 2036, driven by the migration of genomic testing into reimbursed clinical pathways and by the cost advantage providers achieve through high utilization.

By Application: Research & Other Applications Hold the Larger Share in 2026, While Clinical Applications Grows Fastest and Overtakes Research in Value

Based on application, the market is segmented into research and other applications and clinical applications. In 2026, research and other applications account for the larger share of the market, driven by the funding structure through which Thai sequencing capacity was established, with Genomics Thailand committing government funding at a scale that clinical reimbursement does not yet match. Clinical applications expected to register the faster growth and to overtake research applications in absolute value before the end of the forecast period, driven by the migration of genomic testing from research protocols into reimbursed diagnostic pathways. Within clinical applications, oncology holds the largest share of the market and the fastest growth, while reproductive health accounts for the largest share by test volume owing to Thailand's long established national thalassaemia prevention and control program.

By End User: Hospitals & Diagnostic Laboratories Lead in 2026 and Grow Fastest, While Academic & Research Institutes Hold the Largest Installed Capacity

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic and research institutes, and other end users. In 2026, hospitals and diagnostic laboratories account for the largest share of the market and are projected to register the fastest growth, driven by the attribution convention under which market value is recorded against the institution whose requirement generates the demand rather than the facility physically performing the sequencing. Academic and research institutes hold the largest share of the sequencing capacity actually installed in the country, since the high throughput capacity required by Genomics Thailand was installed at academic and national research sites, yet rank second by market value in 2026.

Geographical Analysis

Clinical and academic genomics capability in Thailand is concentrated in a limited number of institutions, principally the medical faculties of Chulalongkorn, Mahidol, and Khon Kaen universities and their affiliated teaching hospitals, together with the National Science and Technology Development Agency and high throughput sequencing platforms sited at Burapha University within the Eastern Economic Corridor. Of the country's approximately 1,450 clinical laboratories and 905 public hospitals under the Office of the Permanent Secretary, capability is deep in Bangkok and a small number of regional university centers and considerably thinner across the 774 community hospitals that make up the bulk of the public network, so that a patient's access to genomic testing depends substantially on where that patient is treated, a dynamic expected to continue shaping demand distribution across the country throughout the forecast period.

Key Companies

Major companies operating in the Thailand next generation sequencing market approach the market from four different starting points. International platform manufacturers supply the sequencing instruments constituting the Thai installed base together with the proprietary consumables those instruments require. Workflow and content suppliers provide the sample preparation, target enrichment, automation, and informatics products consumed across platforms. Diagnostics groups approach the market from established clinical laboratory positions and from the companion diagnostic requirements of their own therapeutic portfolios. Service providers supply sequencing as a completed service rather than the means of producing it.

Some of the prominent players operating in the Thailand next generation sequencing market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), Bangkok Genomics Innovation Public Company Limited (Thailand), Eurofins Scientific SE (Luxembourg), Novogene Co., Ltd. (China), and Next Generation Genomic Co., Ltd. (Thailand).

Thailand Next Generation Sequencing (NGS) Market: Latest Developments from Key Industry Players

• Illumina completed its acquisition of SomaLogic from Standard BioTools on January 30, 2026 for USD 350 million in cash plus up to USD 75 million in near term milestone payments, extending the company from genomics into proteomics.
• Pacific Biosciences divested its short read sequencing by binding assets to Illumina during the first quarter of 2026 for a net cash injection of USD 48.1 million, concentrating its portfolio upon long read sequencing, and launched its SPRQ chemistry in late 2024, which reads sequence, methylation, and chromatin accessibility from a single run.
• F. Hoffmann La Roche entered general commercial availability with its AXELIOS 1 platform during 2026, applying a sequencing by expansion chemistry following an extended early access period with the Broad Institute and the Hartwig Medical Foundation, with the platform offered for research use at launch.
• QIAGEN launched its QIAseq xHYB Long Read Panels in July 2025, target enrichment tools optimized for native long read platforms, and Thermo Fisher Scientific completed its acquisition of Olink for USD 3.1 billion, expanding its proteomics and multiomics capabilities.
• MGI Tech supplied DNBSEQ T7RS sequencing platforms in support of the sequencing of 50,000 Thai genomes under Genomics Thailand, with platforms sited at Burapha University within the Eastern Economic Corridor.
• Bangkok Genomics Innovation signed a memorandum of understanding with the Faculty of Medicine Siriraj Hospital at Mahidol University in July 2023, concluded a cooperation memorandum with BGI Group and Innobic (Asia) to advance colorectal cancer screening through the COLOTECT test, entered a letter of intent with the Agricultural Research Development Agency, and signed an agreement with the Research Division of the Faculty of Medicine at Chulalongkorn University for the development of a CAR T cell product for haematologic cancers.
• Oxford Nanopore introduced duplex sequencing to improve raw read accuracy and a short fragment mode supporting fragments of 200 to 500 base pairs to address formalin fixed and low input material, while its China revenue declined 16% during the first half of 2026 following enhanced export control restrictions.

• The National Health Security Office expanded reimbursable newborn screening to cover 24 rare diseases in 2023 and established a referral system for paediatric rare disease across seven teaching hospitals within the University Hospital Network, and added BRCA1 and BRCA2 testing to the Universal Coverage Scheme benefit package for high risk breast cancer patients and their family members.

Thailand Next Generation Sequencing (NGS) Market Research Summary

Key Questions Answered in the Report